{
"id":"mk19_a_id_t22",
"number":22,
"bookId":"id",
"title":{
"__html":"Preferred Treatment Regimens for Active Tuberculosis"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"c636e2",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 22. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_id_t22"
}
]
},
"Preferred Treatment Regimens for Active Tuberculosis"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f72f32",
"class":"col hd l",
"children":[
"Treatment Phase"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8aaa9e",
"class":"col hd l",
"children":[
"Regimen"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8413c6",
"class":"col hd l",
"children":[
"Comments"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4f2a91",
"class":"cell txt l",
"children":[
"Initial"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6ac5de",
"class":"cell txt l",
"children":[
"Daily INH, RIF, PZA, and EMB",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
" for 56 doses (8 wk) ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"or"
]
}
]
},
" ",
{
"type":"p",
"hlId":"223a98",
"class":"cell txt l",
"children":[
"DOT 5 d/wk for 40 doses (8 wk)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0ddada",
"class":"cell txt l",
"children":[
"Alternative regimens available at ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.cdc.gov/tb/topic/treatment/tbdisease.htm",
"target":"_blank"
},
"children":[
"https://www.cdc.gov/tb/topic/treatment/tbdisease.htm"
]
}
]
},
" ",
{
"type":"p",
"hlId":"9c053e",
"class":"cell txt l",
"children":[
"DOT should be used when medications are administered less than 7 d/wk."
]
},
" ",
{
"type":"p",
"hlId":"2e7143",
"class":"cell txt l",
"children":[
"Pyridoxine 25-50 mg/d is given to all patients at risk for neuropathy",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"; 100 mg/d for patients with peripheral neuropathy."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f11580",
"class":"cell txt l",
"children":[
"Continuation"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1512d7",
"class":"cell txt l",
"children":[
"INH and RIF 7 d/wk for 126 doses (18 wk) ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"or"
]
}
]
},
" ",
{
"type":"p",
"hlId":"25d791",
"class":"cell txt l",
"children":[
"DOT 5 d/wk for 90 doses (18 wk)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"661470",
"class":"cell txt l",
"children":[
"Based on expert opinion, patients with cavitation on the initial chest radiograph and positive cultures at completion of 2 months of therapy should receive a 7-month (31-wk) continuation phase."
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"DOT = directly observed therapy; EMB = ethambutol; INH = isoniazid; PZA = pyrazinamide; RIF = rifampin."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"EMB can be discontinued if drug susceptibility studies demonstrate susceptibility to first-line drugs."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Pregnant women; breastfeeding infants; persons with HIV; patients with diabetes, alcoholism, malnutrition, or chronic kidney disease; patients of advanced age."
],
[
"Recommendations from the Centers for Disease Control and Prevention. Tuberculosis. Treatment for TB disease. TB Regimens for Drug-Susceptible TB. Available at ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.cdc.gov/tb/topic/treatment/tbdisease.htm",
"target":"_blank"
},
"children":[
"www.cdc.gov/tb/topic/treatment/tbdisease.htm"
]
},
". Accessed January 26, 2021."
]
]
}